EUDA Health (EUDA) stock is up about 14% Tuesday morning after the Singapore-based healthcare company disclosed a major expansion of its wellness portfolio. EUDA has secured exclusive global distribution rights of a next-generation immune health supplement developed by biotech firm Chemokine Pte. Ltd.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The rally also comes amid rising institutional activity. Hedge fund XTX Topco Ltd. recently acquired over 16,000 shares of EUDA Health, boosting institutional ownership to 4.35%.
EUDA Eyes 500K Sales in First Year
The newly acquired supplement, branded as Euda Helixe, uses advanced epigenetic technology to modulate gene expression. The company claims this can boost metabolism, vitality, and longevity by activating beneficial genes. Importantly, EUDA aims to sell 500,000 bottles within the first 12 months.
The product will be launched first in Singapore, Malaysia, and China, with plans for global expansion later.
CEO Alfred Lim said, “Securing exclusive distribution rights for such a special product will reinforce our portfolio of wellness product offerings and further diversify our revenue streams.”
EUDA Bets Big on Wellness
EUDA’s entry into the functional nutrition market with its Euda Helixe supplement could be a key growth driver. The company aims to benefit from the rising demand for advanced immunity solutions.
Also, with this launch, the company is set to benefit from the projected growth of the global immunity-boosting food products market, expected to reach $2 trillion by 2034.
Is EUDA Stock a Good Buy?
EUDA stock has declined 35% year-to-date. Looking ahead, investors will be watching for updates on product rollout, revenue impact, and other strategic moves as the company shifts toward wellness innovation.
Overall, on the one-day time frame, EUDA stock is a Sell, according to TipRanks’ easy-to-read technical summary signals. This is based on six Bullish, six Neutral, and 10 Bearish signals.
